Global Prostate Cancer Therapeutics Market was Valued at US$ 11.

4 Bn in 2018,
Development of Innovative Technologies in Screening & Diagnostic Tests
Analyst Speak:

“The Global Prostate Cancer Therapeutics Market was valued around US$ 11.4 Bn by 2018 and
growing at a significant CAGR of 9.0% over next seven years 2019-2025 owing` to development of
innovative technologies in screening & diagnostic tests”

The global prostate cancer therapeutics market accounted for US$ 11.4 Bn in 2018 and burgeoning over
the forthcoming years. Some of the key factors propelling the market growth are various market players
investing in the field of research for developing therapeutic products for treatment of tumors, growing
incidences of glandular cancer, rising demand for non-invasive therapies and development of innovative
technologies in screening & diagnostic tests. However, high cost of tissue biopsy and unfavorable
reimbursement of treatment cost are hindering the growth of the market.

Global prostate cancer therapeutics market segmented on the basis of drug class, route of administration,
distribution channel, and region.

For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15737

Chemotherapeutic Agents Dominate the Global Prostate Cancer Therapeutics Market

Based on drug class, global prostate cancer therapeutics market segmented into immune system modulators,
hormones, chemotherapeutic agents and others. Chemotherapeutic agents segment held considerable
market growth during estimated period. Chemotherapy is the use of any one or combination of cancer-
fighting drugs. It is prescribed in cases of recurrent or advanced prostate cancer. Chemotherapy is given in
cycles of treatment followed by a recovery period. The entire treatment generally lasts three to six months,
depending on the type of chemotherapy medications given. Chemotherapy drugs are given intravenously
(directly into the vein) or by mouth. Once the drugs are absorbed, they enter the bloodstream and travel to
virtually all parts of the body to reach cancer cells that may have spread beyond the prostate.

Asia Pacific Leads the Global Prostate Cancer Therapeutics market

PBI’s global prostate cancer therapeutics market report analyses the market in different regions such as
North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional
analysis. This region is one of the key markets for prostate cancer therapeutics. The region has witnessed
considerable growth in this market due to several governments in this country building awareness programs
with the help of online portals about screening & diagnosis tests, growing awareness of disease, rising
investments by market players in developing immunotherapies and targeted therapies. Europe and North
America are likely to witness steady growth in this market owing to advanced healthcare infrastructure
facilities and huge number of patients affected with this disease.

Strategic Acquisitions are the Key Strategies Adopted by Market Players

Global prostate cancer therapeutics market further reveals that the key player’s increasingly adopting
strategies such as strategic acquisitions and launch of new products to improve market revenue share and
gaining significant geographic presence across the region. For Instance, in 2018, Telix acquired Atlab for
prostate cancer program. This acquisition gives Telix a significant edge in the combination use of PSMA-
targeting therapeutics with androgen-targeting drugs such as Zytiga®2 and Xtandi®3” and bring a
considerable depth of knowledge around antibody-based on PSMA therapeutics.
Key player’s profiles in the report are Endo Pharmaceuticals Inc. (USA), Dendreon Pharmaceuticals LLC
(USA), Debiopharm Group (Switzerland), Bristol-Myers Squibb Company (USA), Bayer AG (Germany),
AstraZeneca Plc. (UK), Astellas Pharma, Inc. (Japan), Amgen, Inc. (USA), Allergan plc (Ireland) and
AbbVie, Inc. (USA).

Precision Business Insights (PBI) in its report titled “Global Prostate Cancer Therapeutics Market:
Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast
2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report
analyses the market value forecast and provides the strategic insights into the market driving factors,
challenges that are hindering the market revenue growth over forecast period. Moreover, the report also
includes the total revenue and volume for the market.

Detailed Segmentation

By Drug Class
o Immune System Modulators
o Hormones
o Chemotherapeutic agents
o Others

By Route of Administration
o Parenteral
o Oral
o Others

By Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o Others

By Geography
o North America
 U.S
 Canada
o Europe
 Germany
 France
 U.K
 Italy
 Spain
 Russia
 Poland
 Rest of Europe
o Asia-Pacific
 Japan
  China
 India
 Australia & New Zealand
 ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and
Others)
 South Korea
 Rest of Asia-Pacific
o Latin America
 Brazil
 Mexico
 Argentina
 Rest of Latin America
o Middle East and Africa (MEA)
 Gulf Cooperation Council (GCC) Countries
 Israel
 South Africa
 Rest of MEA

For more information: https://www.precisionbusinessinsights.com/market-reports/global-prostate-

cancer-therapeutics-market/

Precision Business Insights is one of the leading market research and business consulting firm, which
follow a holistic approach to solve needs of the clients. We adopt and implement proven research
methodologies to achieve better results. We help our clients by providing actionable insights and
strategies to make better decisions. We provide consulting, syndicated and customized market research
services based on our client needs.

Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com